Biogen Shares Drop 6.4% After CELIA Trial Data Misses Primary Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BIIB?
Source: PRnewswire
- Trial Results Disappoint: On May 14, 2026, Biogen's CELIA trial data failed to meet its primary endpoint, resulting in a 6.4% drop in share price, indicating a loss of market confidence in the new drug diranersen, which could impact future funding and R&D plans.
- Primary Endpoint Failure: The CELIA trial did not achieve the expected dose-response on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76, revealing shortcomings in the drug's therapeutic efficacy, which may raise investor concerns about the company's future profitability.
- Legal Consultation Opportunity: Following the stock price decline, Biogen shareholders are encouraged to submit their information to discuss their legal rights, reflecting investor concerns over the company's transparency and accountability, potentially leading to more lawsuits and regulatory scrutiny.
- Future Development Plans: Despite the disappointing trial results, Biogen intends to advance diranersen to registrational development, demonstrating the company's confidence in the drug's potential, although it may face skepticism from the market regarding its R&D direction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 191.910
Low
143.00
Averages
204.45
High
246.00
Current: 191.910
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer’s disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Primary Endpoint
- Trial Results Disappoint: On May 14, 2026, Biogen's CELIA trial data failed to meet its primary endpoint, resulting in a 6.4% drop in share price, indicating a loss of market confidence in the new drug diranersen, which could impact future funding and R&D plans.
- Primary Endpoint Failure: The CELIA trial did not achieve the expected dose-response on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76, revealing shortcomings in the drug's therapeutic efficacy, which may raise investor concerns about the company's future profitability.
- Legal Consultation Opportunity: Following the stock price decline, Biogen shareholders are encouraged to submit their information to discuss their legal rights, reflecting investor concerns over the company's transparency and accountability, potentially leading to more lawsuits and regulatory scrutiny.
- Future Development Plans: Despite the disappointing trial results, Biogen intends to advance diranersen to registrational development, demonstrating the company's confidence in the drug's potential, although it may face skepticism from the market regarding its R&D direction.
See More
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Key Endpoint
- Trial Setback: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in significant losses for investors and a decline in market confidence.
- Future Development Plans: Despite the setback, Biogen intends to advance diranersen to registrational development based on biomarker and efficacy data, indicating the company's belief in the drug's long-term potential.
- Legal Investigation Initiated: Following the disappointing trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made misleading statements that could affect investors' legal rights.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact Levi & Korsinsky for a free evaluation to understand potential legal remedies, ensuring their rights are protected.
See More
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Endpoint
- Significant Stock Drop: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in substantial losses for investors and reflecting a decline in market confidence regarding the company's research capabilities.
- Trial Results Disclosure: The company confirmed in its press release that the CELIA trial did not meet its primary endpoint; however, Biogen plans to advance diranersen to registrational development based on biomarker and efficacy data, indicating confidence in the drug's potential value despite the setback.
- Legal Investigation Initiated: Following the disclosure of the CELIA trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made materially false or misleading statements regarding the trial's failure, which may lead to more investors seeking legal remedies.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact the law firm for a free evaluation, which could provide potential compensation opportunities, further impacting the company's reputation and shareholder confidence.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug to Phase 3 testing despite disappointing mid-stage trial results, as it shows potential in reducing tau protein levels and slowing cognitive decline, particularly at the lowest dose.
- Drug Development Challenges: The company has faced setbacks in its Alzheimer's drug development journey, having successfully launched two drugs to slow cognitive decline, yet its first drug, Aduhelm, was withdrawn due to approval controversies, highlighting market uncertainties.
- Scientific Basis: Biogen's head of development, Dr. Priya Singhal, stated that the latest trial results demonstrate an unprecedented combination of tau reduction and cognitive benefits, emphasizing the necessity to move to Phase 3 testing, indicating progress in dose isolation.
- Competitive Landscape: In the Alzheimer's treatment arena, Biogen faces pressure from rival Eli Lilly, which is also studying drugs aimed at decreasing tau protein levels, underscoring the intense market competition and the urgent demand for innovative therapies.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Primary Endpoint
- Trial Results Disappoint: On May 14, 2026, Biogen's CELIA trial data failed to meet its primary endpoint, resulting in a 6.4% drop in share price, indicating a loss of market confidence in the new drug diranersen, which could impact future funding and R&D plans.
- Primary Endpoint Failure: The CELIA trial did not achieve the expected dose-response on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76, revealing shortcomings in the drug's therapeutic efficacy, which may raise investor concerns about the company's future profitability.
- Legal Consultation Opportunity: Following the stock price decline, Biogen shareholders are encouraged to submit their information to discuss their legal rights, reflecting investor concerns over the company's transparency and accountability, potentially leading to more lawsuits and regulatory scrutiny.
- Future Development Plans: Despite the disappointing trial results, Biogen intends to advance diranersen to registrational development, demonstrating the company's confidence in the drug's potential, although it may face skepticism from the market regarding its R&D direction.
See More
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Key Endpoint
- Trial Setback: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in significant losses for investors and a decline in market confidence.
- Future Development Plans: Despite the setback, Biogen intends to advance diranersen to registrational development based on biomarker and efficacy data, indicating the company's belief in the drug's long-term potential.
- Legal Investigation Initiated: Following the disappointing trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made misleading statements that could affect investors' legal rights.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact Levi & Korsinsky for a free evaluation to understand potential legal remedies, ensuring their rights are protected.
See More
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Endpoint
- Significant Stock Drop: Biogen's shares fell 6.4% on May 14, 2026, after the CELIA trial data failed to meet its primary dose-response endpoint, resulting in substantial losses for investors and reflecting a decline in market confidence regarding the company's research capabilities.
- Trial Results Disclosure: The company confirmed in its press release that the CELIA trial did not meet its primary endpoint; however, Biogen plans to advance diranersen to registrational development based on biomarker and efficacy data, indicating confidence in the drug's potential value despite the setback.
- Legal Investigation Initiated: Following the disclosure of the CELIA trial results, Levi & Korsinsky law firm has launched an investigation into Biogen, focusing on whether the company made materially false or misleading statements regarding the trial's failure, which may lead to more investors seeking legal remedies.
- Investor Action Recommendations: Affected investors are encouraged to gather trading records and contact the law firm for a free evaluation, which could provide potential compensation opportunities, further impacting the company's reputation and shareholder confidence.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
- Clinical Trial Progress: Biogen announced its plan to advance an experimental Alzheimer's drug to Phase 3 testing despite disappointing mid-stage trial results, as it shows potential in reducing tau protein levels and slowing cognitive decline, particularly at the lowest dose.
- Drug Development Challenges: The company has faced setbacks in its Alzheimer's drug development journey, having successfully launched two drugs to slow cognitive decline, yet its first drug, Aduhelm, was withdrawn due to approval controversies, highlighting market uncertainties.
- Scientific Basis: Biogen's head of development, Dr. Priya Singhal, stated that the latest trial results demonstrate an unprecedented combination of tau reduction and cognitive benefits, emphasizing the necessity to move to Phase 3 testing, indicating progress in dose isolation.
- Competitive Landscape: In the Alzheimer's treatment arena, Biogen faces pressure from rival Eli Lilly, which is also studying drugs aimed at decreasing tau protein levels, underscoring the intense market competition and the urgent demand for innovative therapies.
See More
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
- Bitcoin-Linked Stocks Rise: Bitcoin rose 2% as the Senate Banking Committee discussed a regulatory framework for cryptocurrencies, with Coinbase shares jumping nearly 9%, indicating growing market confidence that could drive future growth for related companies.
- Starbucks Upgrade: TD Cowen upgraded Starbucks from hold to buy, raising its price target from $106 to $120, with analysts noting multiple positive sales drivers in a strong market backdrop, suggesting improved performance ahead.
- Ford Stock Surge: Ford shares rose 7%, adding to a 13% gain from Wednesday, as Morgan Stanley highlighted its energy storage business and partnership with CATL, projecting a $3 billion incremental revenue opportunity for Ford's Model e segment.
- Applied Materials Earnings Outlook: Applied Materials saw a 2% increase in shares ahead of its fiscal second-quarter results, with analysts expecting earnings of $2.66 per share and revenue of $7.68 billion, reflecting sustained optimism about semiconductor equipment demand.
See More
